Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. The exodus of key personnel at Google’s Verily
There’s reportedly a rare exodus under way of key personnel from a Google operation, its Verily healthcare “moonshot,” with former employees blaming the mercurial leadership of CEO Andrew Conrad.
A dozen top engineers, scientists and managers have departed since Verily, formerly Google Life Sciences, was launched 3 years ago, according to the Stat website. Read more
4. Report: U.S. IPOs hit 7-year low during 2016 1st quarter
The U.S. market for initial public offerings hit its lowest mark during the 1st quarter since the financial crisis hit in 2008 and 2009 and every flotation was for a healthcare company, according to a report from Renaissance Capital.
Eight IPOs raised a collective $700 million during the quarter, but were only viable due to substantial buys from existing shareholders, according to the report. Read more
3. St. Jude wins CE Mark for expanded suite of cardiac leads
St. Jude Medical said today it won CE Mark approval in the European Union and launched 3 new Quartet left ventricular leads.
The newly released leads are designed for more effective targeting of individual cardiac anatomies for patients who require cardiac resynchronization therapy pacers and defibs, the company said. Read more
2. FDA clears Corindus Vascular Robotics CorPath for peripheral interventions
Corindus Vascular Robotics said today that it won FDA 510(k) clearance for its robotic-assisted CorPath system for peripheral interventions, a year after launching a clinical trial.
The clearance was based on the 20-patient Rapid trial, a prospective, single-arm, single-center study designed to look at the safety and effectiveness of the CorPath device in peripheral artery disease patients with lower-extremity blockages. Read more
1. Colibri Heart Valve looks to raise $25m Series C for TAVR device
Colibri Heart Valve is looking to raise a $25 million Series C for the ready-to-use replacement heart valve it’s developing and has already put $1.25 million into its coffers.
Broomfield, Colo.-based Colibri is running a 1st-in-human trial of the transcatheter aortic valve replacement it’s developing, a pre-mounted, pre-crimped and pre-packaged device that’s designed to be shipped ready to use, according to its website. Read more
The post MassDevice.com +5 | The top 5 medtech stories for March 29, 2016 appeared first on MassDevice.
from MassDevice http://ift.tt/1UT7K50
Cap comentari:
Publica un comentari a l'entrada